Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia 23Lymphoma 21Leukemia, Myeloid, Acute 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Myelodysplastic Syndromes 13Multiple Myeloma 13Breast Neoplasms 13Ovarian Neoplasms 11Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Biphenotypic, Acute 9Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Sarcoma 7Waldenstrom Macroglobulinemia 6Burkitt Lymphoma 6Testicular Neoplasms 5Testicular Germ Cell Tumor 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Ovarian Epithelial 5Blast Crisis 5Myeloproliferative Disorders 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Congenital Abnormalities 4Central Nervous System Neoplasms 4

Interventions

Temozolomide 23Radiotherapy 15Radiation 7Bevacizumab 6temsirolimus 5Sirolimus 5Radiotherapy, Conformal 5Erlotinib Hydrochloride 5Carmustine 5Carboplatin 5Radiotherapy, Intensity-Modulated 4Everolimus 4Vorinostat 3Irinotecan 3veliparib 2tipifarnib 2plerixafor 2pembrolizumab 2atezolizumab 2Surgical Procedures, Operative 2Sorafenib 2Gefitinib 2Fluorodeoxyglucose F18 2Cilengitide 2Chemotherapy, Adjuvant 2vatalanib 1vandetanib 1terameprocol 1tandutinib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × Filgrastim × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡